Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Silencing Cholera's Social Media

May 25, 2016 8:26 am | by PLOS | News | Comments

Understanding how this works has potential for therapeutic purposes.

TOPICS:

New Valeant CEO Discusses Turnaround Plan at Investor Conference

May 25, 2016 8:24 am | by Ryan Bushey, Digital Editor | Articles | Comments

Joseph Papa shed light on the potential strategy for reducing the drug maker's debt load.

TOPICS:

Combination Immunotherapy Set to Become Integral Element of Renal Cell Carcinoma Treatment

May 25, 2016 8:24 am | by Maxime Bourgognon, PharmD, Oncology and Hematology Analyst, GlobalData | Articles | Comments

Combination approaches have the potential to generate twice as many sales in the recurrent RCC market.

TOPICS:
Advertisement

Breakthrough Could Help Sufferers of Deadly Lung Disease

May 24, 2016 1:00 pm | by University of Sheffield | News | Comments

For the first time scientists have identified a molecule that promotes the progression of the disease which affects 6,500 people in the UK.

TOPICS:

Sanofi's Diabetes Drug Faces Scrutiny from FDA

May 24, 2016 10:03 am | by Ryan Bushey, Digital Editor | Articles | Comments

An early review conducted by The Food and Drug Administration (FDA) of Sanofi’s combination diabetes drug iGlarLixi is raising issues related to efficacy.

TOPICS:

Janssen's Stelara Maintained Clinical Remission After Year Of Treatment

May 24, 2016 9:21 am | News | Comments

Janssen Phase 3 data presented for the first time at Digestive Disease Week 2016 showed that a significantly greater proportion of adult patients with moderate to severe Crohn's disease receiving Stelara (ustekinumab) subcutaneous (SC) maintenance therapy were in clinical remission at one year. 

TOPICS:

CDK4/6 Inhibitor Abemaciclib Most Active Against Breast Cancer, NSCLC

May 24, 2016 8:43 am | by Stephanie Guzowski, Editor | News | Comments

New results from a Phase 1 clinical trial that tested Eli Lilly’s investigational CDK4/6 inhibitor indicates that abemaciclib is likely in line to become an FDA-approved CDK4/6 inhibitor.

TOPICS:

Cutting-Edge Findings in Cannabis Research

May 24, 2016 8:42 am | by De Gruyter Open | News | Comments

The recent legalization of cannabis for medical purposes in some US states has reinvigorated the debate over cannabis in Germany. 

TOPICS:
Advertisement

Breast Cancer Drug Discovery Offers Hope for New Treatments

May 24, 2016 8:41 am | by University of Edinburgh | News | Comments

A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.

TOPICS:

Yellow Fever Epidemic Threatens Spread from Angola to China

May 24, 2016 8:39 am | by Elsevier Health Sciences | News | Comments

The spread of yellow fever is a global health threat.

TOPICS:

Catching Metastatic Cancer Cells Before They Grow Into Tumors

May 24, 2016 8:38 am | by Rachel M. Dudek and Lonnie Shea, University of Michigan, The Conversation | News | Comments

“Cure” is a word that’s dominated the rhetoric in the war on cancer for decades.

TOPICS:

GSK Announces Impressive New Data for COPD Drug

May 24, 2016 8:38 am | News | Comments

Analyses remain ongoing and will be the subject of future publications and presentations.

TOPICS:

Astellas, Daiichi Sankyo, and Takeda Announce R&D Collaboration on Biomarker Database

May 23, 2016 2:57 pm | News | Comments

All three firms aim to contribute to the enhancement of health and welfare of people around the world through creating innovative medicine.

TOPICS:

Harvard Licenses Genotyping Platform

May 23, 2016 2:00 pm | by Harvard Gazette | News | Comments

The technology addresses the profound challenge of drug resistance among HIV-infected patients in resource-poor areas.

TOPICS:

One Step Closer to Curing Diabetes

May 23, 2016 1:00 pm | by University of Technology, Sydney | News | Comments

The group is now working with US clinical stage biotechnology company PharmaCyte Biotech to commercialize the research.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading